Dr. Paul Maloof is a board‑certified orthopaedic surgeon specializing in foot and ankle care and has been with Tidewater Orthopaedics since 2013. Originally from Bergen County, New Jersey, he was inspired to pursue a career in medicine by a pediatrician and was drawn to orthopaedic surgery for its ability to make a meaningful, lasting difference in patients’ quality of life.
Dr. Maloof began his academic training at Tufts University in Medford, Massachusetts, where he completed his undergraduate studies. After spending several years in Steamboat Springs, Colorado, he returned to New Jersey to earn his Doctor of Medicine degree at the University of Medicine and Dentistry of New Jersey. He also completed his orthopaedic surgery residency there, serving as administrative chief resident at one of the busiest Level I trauma centers on the East Coast.
Following residency, Dr. Maloof completed advanced fellowship training in foot and ankle surgery at Duke University in Durham, North Carolina. This specialized training allows him to manage a full spectrum of foot and ankle conditions using both surgical and nonsurgical approaches.
Dr. Maloof is one of the only full‑time orthopaedic surgeons in the region dedicated exclusively to comprehensive foot and ankle care. He emphasizes conservative treatment whenever possible, recommending surgery only when nonoperative options have been exhausted. His approach is focused on thoughtful decision‑making, individualized care, and helping patients regain mobility and return to their daily activities with confidence.
Laboratory Rotation
Department of Medicine-Hematology/Oncology, UMDNJ-NJMS Summer 2002
Construction of expression vector to produce stable transfectants with selected siRNA’s. The novelty of this vector caused it to be names pPMSKH1 using my initials.
Research Teaching Specialist
Department of Medicine-Hematology/Oncology, UMDNJ-NJMS 1997 – 1998
Construction of cDNA libraries froom bone marrow cells and screening of clones related to the 7-transmembrane family of receptors. Significant Findings: I. Identified a novel humanspecific gene, HGFIN, now linked to cell cycle checkpoint, and under the control of p53. II. Identified fibronectin as a binding protein for a fibrogenic factor. Consequently, uncovered potential mechanism for bone marrow fibrosis.
Book Chapters
Journal Publications